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Summary
Background The use of electroconvulsive therapy (ECT) is limited by concerns about its cognitive adverse effects. 
Preliminary evidence suggests that administering the glutamate antagonist ketamine with ECT might alleviate cognitive 
adverse effects and accelerate symptomatic improvement; we tested this in a randomised trial of low-dose ketamine.
Methods In this multicentre, randomised, parallel-group study in 11 ECT suites serving inpatient and outpatient care 
settings in seven National Health Service trusts in the North of England, we recruited severely depressed patients, 
who were diagnosed as having unipolar or bipolar depressive episodes defined as moderate or severe by DSM-IV 
criteria, aged at least 18 years, and were able and willing to provide written consent to participate in the study. Patients 
were randomly assigned (1:1) to ketamine (0·5 mg/kg intravenous bolus) or saline adjunctive to the anaesthetic for 
the duration of their ECT course. Patients and assessment and ECT treatment teams were masked to treatment 
allocation, although anaesthetists administering the study medication were not. We analysed the primary outcome, 
Hopkins Verbal Learning Test-Revised delayed verbal recall (HVLT-R-DR) after four ECT treatments, using a Gaussian 
repeated measures model in all patients receiving the first ECT treatment. In the same population, safety was assessed 
by adverse effect monitoring. This trial was registered with International Standard Randomised Controlled Trial 
Number, number ISRCTN14689382.
Findings Between early December, 2012, and mid-June, 2015, 628 patients were screened for eligibility, of whom 
79 were randomly assigned to treatment (40 in the ketamine group vs 39 in the saline group). Ketamine (mean 5·17, 
SD 2·92), when compared with saline (5·54, 3·42), had no benefit on the primary outcome (HVLT-R-DR; difference 
in means –0·43 [95% CI –1·73 to 0·87]). 15 (45%) of 33 ketamine-treated patients compared with 10 (27%) of 
37 patients receiving saline experienced at least one adverse event which included two (6%) of 33 patients who had 
ketamine-attributable transient psychological effects. Psychiatric adverse events were the most common in both 
groups (six [27%] of 22 adverse events in the ketamine group vs seven [54%] of 13 in the saline group).
Interpretation No evidence of benefit for ketamine was found although the sample size used was small; however, the 
results excluded greater than a small to moderate benefit with 95% confidence. The results do not support the use of 
adjunctive low-dose ketamine in routine ECT treatment.
Funding National Institute for Health Research (NIHR) Efficacy and Mechanism Evaluation (EME) programme, 
an MRC and NIHR partnership.
Copyright © The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY license.
Introduction
The naturalistic STAR*D study1 found that about a third 
of patients with depression did not remit even after 
four sequential pharmacological treatments.1 The 
National Institute for Health and Care Excellence (NICE) 
recommends electroconvulsive therapy (ECT) as a 
treatment option for patients with moderate or severe 
depression if they have not responded to multiple drug 
and psychological treatments.2 ECT has greater acute 
effectiveness than pharmacotherapy with a large effect 
size against sham treatment of –0·8,3 and acute 
remission rates of just under 50% in patients not 
responding to previous drug treatments.4 Scottish ECT 
audit data for 20145 reported that about 75% of patients 
with depression, who were most resistant to previous 
treatment, had a good clinical response to ECT.5
The number of patients receiving ECT has fallen 
substantially from around 20 000 a year in England and 
Wales in the 1980s6 to under 5000 by 2006,7 with Scottish 
audit data also showing a continuing gradual decline.5 A 
major factor in this decline appears to be concern about 
a poor risk-benefit balance of ECT because of adverse 
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cognitive side-effects.8 A meta-analysis of 84 studies9 
found that ECT has moderate to large adverse effects on 
cognition when measured up to 3 days after the final 
treatment, especially on anterograde memory, executive 
function, and cognitive processing speed.9 Most deficits 
reverse by 1–2 weeks after the final ECT treatment,9 but 
it is unknown whether persisting adverse effects from 
ECT are masked by positive effects from clinical 
improvement. One uncertainty is whether retrograde 
amnesia or loss of autobiographical memories following 
ECT is persistent,10,11 with a systematic review of seven 
studies8 of patient self-reports finding that persistent 
loss of memories after ECT varied from 29% to 55% in 
individual studies.
Cognitive impairment and effectiveness of treatment 
are both related to the stimulus dose, especially for right 
unilateral ECT,2,3 and there is a clinical trade-off between 
the two effects; a meta-analysis12 found that high-dose 
right unilateral ECT was as effective as moderate-dose 
bitemporal ECT, with a similar cognitive effect profile 
for anterograde memory and verbal fluency; however, 
right unilateral ECT might have benefits for retrograde 
autobiographical memory and reorientation time after 
seizure. Ultra-brief pulse right unilateral ECT (pulse 
width 0·3 ms) was associated with less cognitive 
impairment but was also less effective than brief pulse 
right unilateral ECT (pulse width 1·0–1·5 ms).13 At 
present, the best strategy to maintain the efficacy of ECT 
while minimising cognitive impairment has not been 
established clinically.
The neurotransmitter glutamate has a central role in 
cognition, especially in learning and memory, through its 
effects on synaptic plasticity and the signalling pathway 
involved in long-term potentiation in the hippocampus.14 
Memory impairment after ECT could be a consequence of 
indiscriminate activation or saturation of glutamate 
receptors during the treatment, disrupting hippocampal 
plasticity involved in memory.15 Ketamine, a dissociative 
Research in context
Evidence before this study
The Technology Appraisal of electroconvulsive therapy (ECT) 
by the National Institute for Health and Care Excellence (NICE) 
in 2003 and the updated NICE Clinical Guideline for the 
treatment of Depression (2009) identified ECT as highly 
effective in the acute treatment of depression but that its use 
was limited by cognitive adverse effects, particularly memory 
impairment. Theoretical, animal, and preliminary, 
non-randomised human study evidence suggested that the 
glutamate antagonist ketamine might alleviate the adverse 
cognitive effects of ECT. A series of small randomised trials 
had identified ketamine as having a rapid antidepressant 
effect and it had been hypothesised that it might enhance the 
therapeutic effect of ECT. We searched PubMed with the terms 
“ketamine” and “electroconvulsive therapy” or “ECT” for 
articles published in English up until Nov 30, 2016. We found 
12 randomised trials of varying quality in which ketamine had 
been used as an alternative or adjunctive anaesthetic agent 
compared with a barbiturate anaesthetic or propofol. 
Three small randomised trials reported time to reorientation 
after ECT and found conflicting results. A moderately large 
study reported a benefit for lower dose of ketamine than used 
in the reported study in addition to propofol on a range of 
aspects of memory. Two smaller randomised trials used several 
cognitive tests, both finding no effect of ketamine as an 
augmenting agent, but in one of the trials less impairment 
was found comparing ketamine alone with propofol on 
selected tests of executive function without effect on memory. 
One study reported a better outcome on the Mini Mental 
State Examination on ketamine compared with thiopental but 
the result was not statistically significant. Several studies 
suggest that ketamine might lead to longer seizures with ECT, 
and increase agitation or confusion on awakening, especially 
when given at anaesthetic doses.
Added value of this study
Our study was the first multicentre randomised trial of 
adjunctive sub-anaesthetic ketamine on the effect of bilateral 
brief-pulse ECT as administered in the UK on verbal 
anterograde and autobiographical memory. Its strengths are 
the generalisability to standard UK practice with a robust 
design and analysis. The study adds to evidence from three 
other studies with varying methods that investigated the 
effect of ketamine on cognitive function during ECT assessed 
using several neuropsychological tests. We did not find any 
evidence for an advantage for ketamine treatment on any 
cognitive or efficacy outcomes, with a numerical advantage for 
the saline-treated group on delayed verbal memory (the 
primary outcome) and early and final reduction in depression 
scores. In spite of lower than planned recruitment, we were 
able to exclude more than a small-to-moderate effect size 
benefit for ketamine on the key outcome measures. A minority 
of patients experienced ketamine-related psychological effects 
on awakening from ECT but no serious safety or tolerability 
problems were found.
Implications of all the available evidence
The literature, involving studies with varying methods, is 
inconsistent with regard to whether, and in what specific 
domains, ketamine has benefit when combined with ECT for 
the treatment of depression. The balance of evidence for 
ketamine used as an adjunctive treatment with ECT at the most 
common dose of 0·5 mg/kg is that it does not improve the 
cognitive effect of, or the therapeutic response to, ECT to a 
clinically important degree. However, although the evidence 
does not support giving low-dose ketamine as part of routine 
ECT practice as administered in the UK, it does not rule out its 
possible benefit on cognition in specific patient populations or 
with different ketamine or ECT regimens.
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anaesthetic, analgesic, and psychoto mimetic, inhibits 
N-methyl-d-aspartate (NMDA) receptors, while stimulating 
glutamate release and potentiating glutamate function 
through non-NMDA receptors such as α-amino-3-hydroxy-
5-methylisoxazole-4-propionic acid (AMPA) receptors.16 
Our study is based on preliminary human data from 
retrospective and non-randomised studies that suggested 
that anaesthesia with ketamine, compared with other 
drugs, improves reorientation and word recall after ECT.15 
Ketamine has a rapid antidepressant effect after a single 
dose of intravenous ketamine,17 but evidence is unclear 
about improved symptomatic benefit when ketamine is 
combined with ECT.17,18
In this study, we investigated whether ketamine, 
given as an adjunct to conventional anaesthetics, reduced 
cognitive dysfunction caused by ECT in patients with 
depression who had consented to receive ECT as part 
of their usual care.
Methods
Study design and participants
The ketamine-ECT study was a multicentre, parallel-
group, randomised, double-blind, placebo-controlled, 
superiority trial of ketamine added to standard ECT 
during anaesthetic induction in patients with severe 
depression. The hypotheses and protocol have been 
published19 and are also available online.
Recruitment was from secondary care settings referring 
into 11 ECT suites in seven National Health Service (NHS) 
Trusts in the North of England (appendix). Recruited 
patients had a diagnosis of depression and had already 
consented to having ECT after having being referred for 
the study by their treating consultant psychiatrist. 
Inclusion criteria were a diagnosis of a unipolar or bipolar 
depressive episode defined as moderate or severe (DSM-
IV criteria), age of at least 18 years, and the ability and 
inclination to provide written consent to participate in the 
study. They were also required to have a verbal IQ 
equivalent to 85 or greater, be sufficiently fluent in English 
to validly complete neuropsychological testing, and 
medically fit to receive ketamine (based on American 
Society of Anesthesiologists score of 1, 2, or stable 3 and 
the opinion of an anaesthetist). Exclusion criteria were 
detention under the Mental Health Act (1983, as amended 
in 2007); inability to give informed consent; a primary 
psychotic or schizoaffective disorder; current primary 
obsessive compulsive disorder, anorexia nervosa, history 
of drug or alcohol dependence (DSM-IV criteria); ECT 
in the past 3 months (amended from 6 months on 
May 22, 2013); known hypersensitivity or contraindication 
to ketamine, concomitant medications used for ECT, or 
excipients in these injections; evidence of organic brain 
disease including dementia or substantial medical illness 
affecting neuropsychological function; use of etomidate as 
an induction agent; pregnancy or not taking adequate 
contraception; breastfeeding; and a score of less than 24 
on the Mini Mental State Examination (MMSE).
Ethical approval was granted by the North West-
Liverpool East Research Ethics Committee (REC Ref No. 
12/NW/0021) on Jan 25, 2012. Clinical Trial Authorisation 
was given by the Medicines and Healthcare products 
Regulatory Agency (23148/0004/001-0001). All participants 
gave written informed consent to participate. The study is 
registered with the International Standard Randomised 
Clinical Trial Number registry, number ISRCTN14689382, 
and with the EU Clinical Trials register, EudraCT number 
2011-005476-41.
Randomisation and masking
Patients were randomly assigned (1:1) to receive either 
ketamine or saline as anaesthetic for their ECT treatment. 
Randomisation was done by the Christie Hospital Clinical 
Trials Co-ordination Unit (CTU) by use of permuted 
block randomisation, which varied randomly between 
four and eight, and was stratified by NHS Trust. The 
randomisation code, held by the CTU, was provided to the 
local site pharmacies. At randomisation, the site research 
assistant telephoned the CTU with participant details and 
the CTU then contacted the local site pharmacy to prepare 
the investigational drug according to the randomisation 
code. Ampoules containing clear solutions of ketamine 
(10 mg/mL) or 0·9% sodium chloride solution (saline) 
were provided in secondary tamperproof trial packaging, 
while still retaining their original labelling. Both patients 
and assessment and ECT treatment teams were masked 
to treatment allocation, although the anaesthetists 
administering the study medication were not. The 
anaesthetist broke the seal away from the psychiatric 
ECT team, drew up the trial medication into a syringe, 
and disposed of the ampoule without revealing which 
drug was being administered. Researchers responsible 
for outcome assessment did not attend ECT sessions. 
To assess success of masking, patients and assessors 
were invited to complete a questionnaire to indicate 
suspected treatment group after four ECTs and at the end 
of the ECT course, and the results were sent directly to the 
CTU in a sealed envelope for data entry.
Procedures
Standard ECT protocols based on the Royal College of 
Psychiatrists’ ECT Handbook, 2nd edn20 were agreed 
between centres, with ECT treatments scheduled twice 
a week using Thymatron IV (Somatics, LLC, Lake Bluff, 
IL, USA) or Mecta Spectrum 5000 (Mecta Corp, 
Lake Oswego, OR, USA) devices depending on site. 
After pre-oxygenation with 100% oxygen, anaesthesia 
given for ECT treatment was propofol (or thiopental if 
clinically indicated) combined with the muscle relaxant 
suxamethonium and remained the same for all ECT 
treatments unless change was required for clinical 
reasons. Ketamine (0·5 mg/kg) or saline was given as 
a slow intravenous bolus directly before anaesthetic 
induction at each treatment. Electrode placement 
was standard bitemporal or right unilateral (D’Elia) 
For hypotheses and protocol 
see http://research.bmh.
manchester.ac.uk/ketECT
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placement.20 After confirmation of complete muscle 
relaxation (cessation of pedal muscle fasciculation), 
seizure was induced by giving patients constant-current 
brief pulse stimuli (0·5 ms pulse width, increased to 
1·0 ms if clinically indicated). Treatment dose was 
1·5 times seizure threshold for bitemporal electrode 
placement, and 4–6 times threshold for right unilateral 
electrode placement on the basis of rapid stimulus 
titration in the first ECT session. The stimulus 
parameters remained the same until after the fourth 
treatment unless requiring change for clinical reasons. 
ECT treatments were administered twice weekly to the 
end of the ECT treatment course, which was decided 
by each patient’s treating clinical team. Standard 
operating procedures were used to identify criteria for 
an adequate seizure, for re-stimulation, and for ECT 
dosage adjustments to ensure adequate seizures and to 
optimise clinical response. Following the ECT course, 
patients were treated as usual by their clinical team; if a 
further course of ECT was started during the follow-up 
period they were withdrawn from the study.
Oral psychotropic medication was continued by the 
treating clinical team and not changed during the first 
four ECT treatments, and if possible, until the end of 
the course of ECT, unless required for safety or clinical 
reasons. The goal was to treat patients to remission 
(defined as Montgomery-Åsberg Depression Rating Scale 
[MADRS] ≤10),2 but the final decision to finish ECT 
treatment rested with the treating clinical team.
Outcomes
The primary outcome was anterograde verbal memory 
measured by delayed recall on the Hopkins Verbal 
Learning Test-Revised (HVLT-R-DR)21 after four ECT 
treatments (±1 treatment); originally Controlled Oral Word 
Association Test (COWAT) category fluency and Autobio-
graphical Memory Interview-Short Form (AMI-SF) had 
been included as primary outcomes, but these were not 
pursued, as discussed in the statistical analysis. Secondary 
neuro psychological assessments were HVLT-R-DR at the 
end of the course of ECT, and at 1 and 4 months of follow-
up after ECT; at all timepoints, measurements were taken 
using other HVLT tests (learning, retention, recognition 
discrimination), COWAT, AMI-SF, Medical College of 
Georgia Complex Figure Test (MCGCFT), clinical digit 
span forwards and backwards, and Self-reported Global 
Self Evaluation of Memory (GSE-My). Reorientation was 
assessed 30 min after each ECT treatment (instrument 
references given in appendix). Secondary clinical efficacy 
measures were assessed at baseline, weekly during the 
ECT course, within 5 days of the final ECT, and at 1 and 
4 months after the end of ECT, and consisted of MADRS,22 
the Clinical Anxiety Scale (CAS), Clinical Global 
Impression (CGI), the 19-item Brief Psychiatric Rating 
Scale (BPRS; which included an elevated mood item), 
the Quick Inventory of Depressive Symptomatology—
Self Report (QIDS-SR), and quality of life using the 
Figure: Trial profile
*Modified intention-to-treat was defined as all patients randomised to treatment who received a first ECT. 
Analysis required one or more valid postbaseline assessments: numbers analysed were 32–33 in the ketamine 
group and 35–36 in the saline group depending on outcome measure.
628 patients receiving ECT assessed 
 for eligibility
549 ineligible
 294 under Mental Health Act
 69 did not give consent
 66 other or unknown
 44 did not have mental capacity
 35 recently had ECT 
 33 met other exclusion criteria
 4 already participated in trial
 4 clinical team decision79 patients randomly assigned
40 randomly assigned to ketamine
35 began ECT
33 reached mid-ECT
28 reached end of treatment
25 reached 1-month follow-up
19 reached 4-month follow-up
33 included in modified intention-
 to-treat analysis*
39 randomly assigned to saline
37 began ECT
36 reached mid-ECT
32 reached end of treatment
23 reached 1-month follow-up
18 reached 4-month follow-up
37 included in modified intention-
 to-treat analysis*
5 excluded
 3 withdrew from ECT
 1 non-availability of
ketamine
 1 ECT in unapproved 
        study suite
2 met exclusion criteria
5 lost to follow-up
 2 uncontactable 
 1 Mental Health Act
 1 withdrew consent
 1 lost mental capacity
3 lost to follow-up
 2 withdrew consent
 1 required further ECT
6 lost to follow-up
 3 uncontactable
 2 required further ECT
 1 unavailable
2 excluded
 1 withdrew from ECT
 1 medical 
 contraindication
1 withdrew consent
4 lost to follow-up
 3 uncontactable 
 1 Mental Health Act
9 lost to follow-up
 4 uncontactable
 2 withdrew consent
 3 required further ECT
5 lost to follow-up
 2 uncontactable
 1 Mental Health Act
 1 withdrew consent
 1 required further ECT
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EuroQol 3-level version (EQ-5D-3L). We also calculated 
occurrence and time to remission (MADRS ≤10) and 
response (≥50% decrease in MADRS from baseline) 
during the ECT treatment course and noted the number of 
patients worsening during follow-up (defined as a MADRS 
increase of ≥4 points and CGI-severity increase of ≥1 point 
to CGI-severity ≥3 from the end of treatment assessment).
Statistical analysis
We based the sample size on a moderate standardised 
effect size for the difference between ketamine and saline 
(0·5–0·6). We originally powered the study to detect a 
standardised effect size of 0·51 with 80% power, with a 
two-sided p value of 0·05 (after Bonferroni correction), for 
three primary cognitive outcome measures (HVLT-R-DR, 
COWAT category fluency, and AMI-SF). This required 
80 patients per group assuming a 5% attrition rate after 
four ECT treatments. Following initial slow recruitment, 
the recruitment target was revised to 100 patients 
(50 patients per group) with the consent of the funder and 
Data Monitoring and Ethics Committee (DMEC), and 
a single primary outcome, the HVLT-R-DR specified. 
Assuming a 5% attrition for the primary outcome time-
point, this sample size gives 80% power to detect an effect 
size of 0·57, with a two-sided p value of 0·05.
The full statistical analysis plan was agreed with DMEC 
before study completion and before unmasking (appendix). 
Statistical analysis was based on a modified intention-to-
treat population, defined as all patients who received the 
first ECT, depending on the availability of data. Missing 
efficacy data were filled in by pro-rating on the provision 
that at least 70% of items in the same scale had been 
completed; but was not used for neuropsychological 
outcomes. Neuropsychological assessments were linked to 
ECT treatments; mid-ECT (after 4±1 ECT) within 5 days of 
previous ECT treatment, and end of treatment (after last 
ECT) within 12 days of previous ECT treatment were 
deemed valid (appendix). This prespecified assessment 
window was broader than original protocol timings (3 and 
5 days, respectively) because of clinical unpredictability of 
ECT treatment (eg, missed sessions, uncertainty about end 
of treatment), which hampered completing assessments 
within the original timeframes. We did a sensitivity 
analysis for the primary outcome measure limited to 
participants with completed assessments within the 
original protocol timings.
For each neuropsychological outcome a Gaussian 
repeated measures model with an unstructured covariance 
matrix was fitted by use of the mixed procedure in Stata, 
by use of all available data taking into account correlations 
between measures for each patient (this was a modification 
of the statistical analysis plan to avoid having to apply four 
models per outcome). On the basis of the observed mean 
time from baseline, 2, 6, 10, and 22 weeks were selected as 
the nominal time values in the repeated measures models. 
The treatment effect at each timepoint was assessed by the 
time by treatment interaction adjusting for prespecified 
Ketamine group 
(n=33)
Saline group 
(n=37)
Mean age, years 52·5 (11·9) 56·4 (12·4)
Sex, female 22 (67%) 22 (60%)
Mean years in full-time 
education
13·7 (4·0) 13·5 (3·2)
Ethnicity white 31 (94%) 35 (95%)
Married or current partner 13 (39%) 19 (51%)
Mean IQ 105·1 (11·3) 109·9 (11·0)
MMSE 28·8 (2·0) 29·0 (1·2)
Illness characteristics
Inpatient 11 (33%) 21 (57%)
Bipolar disorder 4 (12%) 7 (19%)
Age of onset (years) 29·6 (14·0) 32·2 (17·0)
Number of depressive 
episodes (lifetime)
4·9 (4·4) 5·3 (5·2)
Number of hypomanic/
manic episodes
0·3 (1·0) 0·5 (1·8)
Previous ECT 18 (55%) 16 (43%)
Family history of depression 23 (70%) 18 (49%)
Family history of bipolar 
disorder
2 (6%) 10 (27%)
Current depressive episode
MADRS score 31·8 (7·4) 35·2 (8·4)
Melancholia no psychosis 26 (79%) 25 (68%)
Psychosis ± melancholia 3 (9%) 8 (22%)
Median duration, months 14 (7–38) 8 (3·5–20·5)
MGHS score 4·8 (2·6) 4·0 (3·4)
Comorbidity
Anxiety disorder or 
secondary OCD
16 (48%) 18 (49%)
Other psychiatric disorder 1 (3%) 0 (0%)
Medical illness 12 (36%) 9 (24%)
Physical signs
Weight, kg 82·2 (17·1) 77·2 (17·7)
BMI, kg/m² 29·3 (5·8) 28·8 (6·7)
Systolic blood pressure, 
mmHg
132·9 (18·0) 126·1 (17·2)
Psychotropic medication
SSRI 10 (30%) 14 (38%)
SNRI 16 (48%) 15 (41%)
TCA 4 (12%) 8 (22%)
MAOI 0 (0) 1 (3%)
Other antidepressant 14 (42%) 10 (27%)
Antipsychotic 18 (55%) 26 (70%)
Lithium 7 (21%) 5 (14%)
Antiepileptic mood stabiliser 5 (15%) 7 (19%)
Hypnotic/anxiolytic 17 (52%) 21 (57%)
Data are mean (SD), n (%), or median (IQR). BMI=body-mass index. 
IQ=intelligence quotient. MAOI=monoamine oxidase inhibitor. 
MGHS=Massachusetts General Hospital Scale. MMSE=Mini Mental State 
Examination. OCD=obsessive compulsive disorder. SNRI=serotonin and 
noradrenaline reuptake inhibitor. SSRI=selective serotonin reuptake inhibitor. 
TCA=tricyclic antidepressant.
Table 1: Baseline demographics and clinical characteristics of participants
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covariates: baseline value, age at randomisation, sex, 
baseline degree of treatment resistance (Massachusetts 
General Hospital Scale [MGHS] score), and electrode 
placement (bitemporal or right unilateral). Only 
participants with at least one postbaseline assessment 
could therefore be included in the analysis. For the AMI-
SF, we used scores measured at each timepoint rather 
than percentage of baseline recall (presented in the 
appendix). All repeated measures model analyses involved 
the use of robust standard errors and associated 
confidence intervals and p values (allowing for non-
normality and constraints in the ranges of some of the 
cognitive outcomes).
We analysed acute efficacy data for the ECT treatment 
period over time using a random effects (random 
intercepts and slopes) analysis of covariance model with 
time in weeks since first ECT as a continuous variable 
with data provided until the end of treatment assessment. 
The fixed covariates were treatment, time by treatment 
interaction, and the same prespecified baseline char-
acteristics as were used for the neuro psychological 
repeated measures analyses. For each model, two 
correlated random effects terms were included to capture 
between-subject variation in the intercept and slopes, 
assuming that people might improve at different rates. 
All models involved the use of robust standard errors and 
associated confidence intervals and p values. We did a 
sensitivity analysis for the MADRS using time since 
randomisation instead of from first ECT to investigate 
whether delay in starting ECT after randomisation 
affected the results. For remission and response binary 
variables, we analysed the frequency and cumulative 
frequency of first occurrence according to the week 
recorded using Kaplan-Meier plots and Cox analyses 
(adjusting for the same baseline variables as for 
continuous variables, including baseline MADRS). Time 
to event was defined as the difference between the first 
ECT date and the date of assessment, with last known 
efficacy assessment date used for censored patients. We 
compared the proportion of patients worsening at follow-
up assess ment (provided that patients had attended at 
least one follow-up timepoint) using Fisher’s exact test.
We analysed statistical data using Stata Release 13 
(Stata Statistical Software, StataCorp, TX, USA) and IBM 
SPSS Statistics 22.0 (IBM, Armonk, NY, USA).
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all data in the study and made the decision to submit the 
report for publication.
Results
628 patients received ECT in participating sites during 
the period of recruitment (early December, 2012, to 
mid-June, 2015). 202 (32%) of 628 patients were deemed 
potentially eligible from preliminary clinical and case 
note information, of whom 159 (79%) were invited to 
see the research team, 111 (55%) agreed to do so, and 
79 (39%) were randomly assigned (1:1) to treatment 
(40 in the ketamine group vs 39 in the saline group; 
figure). Eligible patients were younger than those who 
were ineligible (mean age 57·9 [SD 13·6] vs 64·6 
[SD 15·3], p<0·001) with an equal proportion being 
women (69·4% vs 66·0%). Included patients were 
younger than non-included potentially eligible patients 
(55·2 [SD 13·1] vs 59·8 [SD 13·7] years, p=0·02). The 
main reasons for non-progression were detention under 
the Mental Health Act (294 of 628, 47%), followed by 
impaired capacity in voluntary patients (44, 7%). 
70 patients (89% of 79 randomly assigned to treatment) 
formed the modified intention-to-treat population (33 in 
the ketamine group vs 37 in the saline group). The 
exclusions to the modified intention-to-treat population 
included two patients in the ketamine group who had 
commenced ECT but were discovered retrospectively 
to meet exclusion criteria leading to ECT being 
discontinued (undiagnosed brain tumour, re-diagnosis 
of dementia). Exclusion from the modified intention-to-
treat population occurred before analysis since their 
conditions were potential confounds for the cognitive 
outcome measures. Three patients, under-dosed with 
ketamine by 13–33% in error (two for the whole ECT 
course and one for only two doses), and one patient in 
Ketamine group 
(n=33)
Saline group (n=37) p value
Dose of drugs for induction
Propofol (mg) 127·1 (33·9) 151·4 (43·6) 0·01
Thiopental (mg)* 334·9 (53·4) 150 ··
Suxamethonium (mg) 49·8 (15·0) 50·8 (14·3) 0·77
Ketamine or saline (mg)† 40·8 (8·1) 38·8 (8·1) 0·32
ECT-related variables
Bilateral ECT at initiation‡ 28 (85%) 34 (92%) 0·46
Bilateral ECT at mid-ECT‡ 28 (83%) 32 (89%) 0·26
Stimulus dose (mC) 306·0 (213·6) 276·5 (155·6) 0·51
Motor seizure duration (s) 15·2 (5·6) 14·9 (5·2) 0·83
EEG seizure duration (s) 24·4 (10·4) 26·2 (7·8) 0·42
Reorientation after seizure
Items correct at 30 min (of 5) 4·65 (0·50) 4·69 (0·34) 0·69
Proportion of sessions each participant 
was reoriented at 30 min§
0·93 (0·14) 0·94 (0·11) 0·75
Data are mean (SD) or n (%). Data exclude first ECT session, which was a titration session, and use last stimulation in 
case of re-stimulation within a treatment session. Reorientation was assessed by use of five questions (name, place, 
day of the week, age, and birthday).23 EEG=electroencephalogram. *Two patients from the ketamine group received 
thiopental from initiation, a further two patients from the ketamine group and one from the saline group switched to 
thiopental from propofol during the ECT course. †Saline dose is mg equivalent of ketamine. One patient in the 
ketamine group withdrew consent to the study drug after the first ECT but continued in the trial. ‡Over the full course 
of ECT two patients treated with saline and four treated with ketamine switched from unilateral to bilateral ECT, and 
one patient from each group switched from bilateral to unilateral ECT. §Being reoriented was defined as correctly 
answering at least 4 of 5 orientation questions.
Table 2: ECT treatment variables and re-orientation in the two treatment groups
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Ketamine group Saline group Repeated measures analysis
Mean score (SD) n Mean score (SD) n Difference ketamine–saline 
adjusted for baseline (95% CI)
p value
HVLT-R
Delayed recall
Baseline 6·12 (2·69) 33 5·86 (3·63) 37 ·· ··
Mid-ECT* 5·17 (2·92) 29 5·54 (3·42) 35 –0·43 (–1·73 to 0·87) 0·51
End of treatment 5·69 (2·80) 26 5·44 (3·18) 32 –0·04 (–1·22 to 1·13) 0·94
1-month follow-up 6·70 (2·67) 23 7·26 (2·63) 23 –0·53 (–1·66 to 0·60) 0·36
4-month follow-up 6·63 (3·17) 19 8·11 (2·83) 18 –1·40 (–2·91 to 0·12) 0·07
Total learning
Baseline 20·0 (4·1) 33 20·8 (6·7) 37 ·· ··
Mid-ECT* 20·2 (5·8) 29 21·0 (5·4) 36 –0·11(–2·04 to 1·81) 0·91
End of treatment 19·8 (4·9) 26 21·2 (5·6) 32 –0·96 (–2·97 to 1·06) 0·35
1-month follow-up 22·3 (4·7) 23 23·5 (5·6) 23 –0·50 (–2·54 to 1·54) 0·63
4-month follow-up 21·6 (5·0) 19 24·1 (6·1) 18 –1·12 (–3·68 to 1·44) 0·39
Retention
Baseline 73·3 (27·8) 33 65·2 (32·9) 37 ·· ··
Mid-ECT* 58·6 (25·0) 29 62·4 (31·8) 35 –5·12 (–18·0 to 7·8) 0·44
End of treatment 69·4 (26·6) 26 58·7 (26·4) 32 6·97 (–4·88 to 18·8) 0·25
1-month follow-up 73·3 (24·0) 23 77·1 (16·1) 23 –3·22 (–13·3 to 6·9) 0·53
4-month follow-up 74·3712 (23·3) 19 85·5 (18·7) 18 –11·97 (–24·0 to 0·10) 0·052
Recognition discrimination
Baseline 9·45 (2·05) 33 8·16 (3·48) 37 ·· ··
Mid-ECT* 8·48 (2·81) 29 8·54 (2·84) 35 –0·64 (–1·72 to 0·44) 0·25
End of treatment 8·58 (2·90) 26 9·66 (2·10) 32 –1·59 (–2·76 to –0·42) 0·008
1-month follow-up 9·52 (2·33) 23 9·52 (2·33) 23 –0·59 (–1·61 to 0·43) 0·25
4-month follow-up 10·42 (1·43) 19 9·56 (2·97) 18 0·51 (–0·78 to 1·80) 0·44
COWAT
Letter fluency
Baseline 33·8 (13·1) 33 36·1 (14·3) 37 ·· ··
Mid-ECT* 31·5 (12·9) 29 36·1 (13·2) 36 –1·82 (–5·86 to 2·23) 0·38
End of treatment 33·0 (13·4) 26 34·2 (13·5) 32 –1·01 (–5·57 to 3·54) 0·66
1-month follow-up 35·6 (13·4) 23 39·5 (14·1) 23 –1·52 (–5·74 to 2·70) 0·48
4-month follow-up 37·6 (13·2) 19 38·6 (10·7) 18 –0·18 (–5·17 to 4·80) 0·94
Category fluency
Baseline 15·8 (5·5) 33 16·8 (5·3) 37 ·· ··
Mid-ECT* 15·9 (5·3) 29 16·4 (4·2) 36 0·03 (–1·73 to 1·78) 0·97
End of treatment 14·3 (5·1) 26 15·8 (4·2) 32 –1·29 (–3·15 to 0·57) 0·17
1-month follow-up 16·5 (5·6) 23 17·1 (4·1) 23 –0·23 (–2·43 to 1·96) 0·84
4-month follow-up 17·8 (4·6) 19 18·1 (5·3) 18 –0·35 (–2·90 to 2·21) 0·79
AMI-SF
Baseline 45·5 (9·2) 33 44·2 (10·3) 37 ·· ··
Mid-ECT* 39·3 (9·0) 29 38·0 (10·0) 36 –0·67 (–3·16 to 1·81) 0·60
End of treatment 34·7 (9·8) 25 34·8 (10·5) 32 –0·11 (–3·63 to 3·41) 0·95
1-month follow-up 35·1 (10·0) 23 35·4 (10·4) 23 –0·46 (–3·91 to 3·00) 0·80
4-month follow-up 37·4 (10·1) 19 38·9 (8·4) 16 –0·70 (–3·93 to 2·54) 0·67
MCGCFT
Copy
Baseline 34·6 (2·4) 33 33·4 (4·3) 37 ·· ··
Mid-ECT* 33·9 (4·0) 29 34·1 (3·2) 36 –0·66 (–2·27 to 0·95) 0·42
End of treatment 34·6 (2·0) 26 34·4 (2·4) 32 –0·54 (–1·66 to 0·57) 0·34
1-month follow-up 35·3 (1·2) 23 34·4 (3·0) 23 –0·41 (–1·61 to 0·78) 0·50
4-month follow-up 35·2 (1·1) 19 35·0 (1·1) 18 –0·49 (–1·32 to 0·34) 0·25
(Table 3 continues on next page)
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the ketamine group who declined the study drug during 
the ECT course, were retained in the analysis.
At baseline, patients in the modified intention-to-treat 
population mostly had unipolar major depressive disorder 
with a severe current episode that had failed to respond to 
about four pharmacological treatments. The saline and 
ketamine groups were similar on demographics and 
clinical characteristics (table 1).
Most patients received propofol as the induction agent 
(table 2). Patients in the ketamine group received a 
16% lower dose of propofol compared with the saline 
group since anaesthetists took ketamine into account in 
calculating the dose for anaesthesia.24 The two groups 
were similar with regard to ECT stimulus dose, seizure 
duration, and degree of reorientation at 30 min (table 2). 
Masking of treatment allocation was successful as 
assessed by questionnaire; patient guesses were correct 
in 28 (48%) of 58 patients who completed the 
questionnaire at mid-ECT and 30 (56%) of 54 patient 
guesses at the end of treatment, while 35 (56%) of 
63 assessor guesses at mid-ECT and 28 (51%) of 
55 assessor guesses at the end of treatment were correct, 
which did not differ significantly from chance.
The timing of valid neuropsychological assessments 
was similar in the two groups in terms of number of 
previous ECT treatments (mean 4·2 treatments [SD 0·6] 
in the ketamine group vs 4·0 [0·5] in the saline group at 
mid-ECT; 11·4 treatments [4·1] in the ketamine group vs 
11·3 [4·5] in the saline group at end of treatment) and 
number of days between previous ECT session and 
assessment (2·2 days [1·2] in the ketamine group vs 1·8 
[1·0] in the saline group at mid-ECT; 4·0 days [2·4] in 
the ketamine group vs 4·2 [2·4] in the saline group at 
end of treatment). The assessments done at 1 month 
(10·3 weeks [2·2] in the ketamine group vs 10·0 [2·7] in 
the saline group) and 4 months (21·9 weeks [3·4] in the 
ketamine group vs 21·8 [4·1] in the saline group) after 
the first ECT were done at a similar number of weeks.
For neuropsychological outcomes, there was no signif-
icant difference between groups on the HVLT-R-DR test 
Ketamine group Saline group Repeated measures analysis
Mean score (SD) n Mean score (SD) n Difference ketamine–saline 
adjusted for baseline (95% CI)
p value
(Continued from previous page)
Immediate recall
Baseline 19·0 (8·8) 33 17·9 (7·6) 37 ·· ··
Mid-ECT* 18·6 (8·6) 29 18·4 (7·2) 36 –0·35 (–3·09 to 2·39) 0·80
End of treatment 19·0 (7·4) 26 16·6 (6·2) 32 0·61 (–1·77 to 3·00) 0·61
1-month follow-up 19·5 (6·0) 23 19·7 (6·7) 23 –1·96 (–4·43 to 0·50) 0·12
4-month follow-up 23·8 (8·1) 19 21·5 (6·4) 18 –0·27 (–3·05 to 3·58) 0·88
Delayed recall
Baseline 18·9 (7·7) 33 17·6 (6·9) 36 ·· ··
Mid-ECT* 17·7 (8·2) 29 17·7 (7·5) 35 –0·77 (–3·64 to 2·10) 0·60
End of treatment 17·6 (5·9) 25 15·3 (5·3) 32 0·21 (–1·94 to 2·36) 0·85
1-month follow-up 18·9 (6·4) 22 19·0 (6·5) 23 –2·32 (–5·00 to 0·37) 0·09
4-month follow-up 22·9 (9·7) 19 20·8 (6·8) 18 0·29 (–3·79 to 4·36) 0·89
Digit span
Forward
Baseline 5·70 (1·07) 33 5·84 (1·21) 37 ·· ··
Mid-ECT* 5·48 (0·95) 29 6·00 (1·04) 36 –0·46 (–0·81 to –0·11) 0·009
End of treatment 5·88 (1·34) 26 5·84 (1·02) 32 0·003 (–0·49 to 0·50) 0·99
1-month follow-up 5·91 (1·04) 23 5·83 (1·11) 23 0·002 (–0·46 to 0·46) 0·99
4-month follow-up 5·68 (1·20) 19 5·72 (0·89) 18 –0·18 (–0·64 to 0·27) 0·43
Backwards
Baseline 3·64 (1·17) 33 3·95 (1·10) 37 ·· ··
Mid-ECT* 3·86 (1·38) 29 3·94 (1·01) 36 0·17 (–0·25 to 0·59) 0·42
End of treatment 3·88 (1·21) 26 3·97 (0·97) 32 –0·04 (–0·50 to 0·42) 0·87
1-month follow-up 3·87 (1·25) 23 4·13 (1·29) 23 –0·14 (–0·70 to 0·43) 0·63
4-month follow-up 3·89 (1·05) 19 4·06 (1·06) 18 –0·08 (–0·65 to 0·50) 0·80
Modified intention-to-treat repeated measures analysis was adjusted for age at randomisation, sex, baseline degree of treatment resistance, electrode placement (bilateral or 
unilateral), and baseline value of each outcome. Negative values favour saline. AMI-SF=Autobiographical Memory Interview-Short Form. COWAT=Controlled Oral Word 
Association Test. HVLT-R=Hopkins Verbal Learning Test-Revised. MCGCFT=Medical College of Georgia Complex Figure Test. *Mid-ECT for these were approximately 2 weeks 
after baseline, but varied between patients.
Table 3: Neuropsychological task outcomes in participants randomised to saline or ketamine
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at the primary outcome timepoint (mid-ECT) or at other 
timepoints (table 3, appendix). The sensitivity analysis 
excluding assessments 4 and 5 days after the last ECT at 
mid-ECT (n=4) and assessments 6–12 days after the last 
ECT at end of treatment (n=11) did not significantly 
change the results (appendix). The same pattern was 
seen for all secondary neuropsychological outcomes, 
with isolated significant advantage for the saline-treated 
group at mid-ECT for forward digit span and at end of 
treatment for HVLT-R recognition discrimination 
(table 3). At mid-ECT the standardised effect sizes 
(Cohen’s d) were –0·13 (95% CI –0·54 to 0·27) for 
HVLT-R-DR, 0·01 (–0·37 to 0·38) for COWAT category 
fluency, and –0·07 (–0·33 to 0·19) for AMI-SF. For 
the same measures, effect sizes at end of treatment were 
–0·01 (–0·41 to 0·38) for HVLT-R-DR, –0·28 
(–0·68 to 0·12) for COWAT category fluency, and –0·01 
(–0·36 to 0·33) for AMI-SF. Subjective memory rated on 
the GSE-My did not differ between treatments with both 
groups rating ECT as causing a slight average worsening 
of memory, although self-assessment of current memory 
changed little through the ECT course (appendix).
There was no significant difference between the efficacy 
treatment slopes during the ECT treatment period (table 4, 
MADRS shown in the appendix). The marginal differences 
at specific timepoints for the MADRS that were calculated 
from the time by treatment interaction were similar: 
–2·2 (95% CI –5·6 to 1·3) at 2 weeks, –3·0 (–8·4 to 2·3) at 
4 weeks, and –3·9 (–11·8 to 3·9) at 6 weeks. The marginal 
effect size at 2 weeks was –0·20 (–0·50 to 0·12) and 
at 6 weeks (based on SD at the end of treatment) –0·37 
(–1·12 to 0·37) in favour of saline. A sensitivity analysis of 
the MADRS based on time since randomisation rather 
than first ECT showed similar results (appendix). In the 
ketamine group 13 (39%) of 33 patients reached remission 
(MADRS ≤10) during the acute treatment phase compared 
with 13 (35%) of 37 in the saline group; similarly, responses 
(MADRS ≥50% decrease from baseline) were 16 (49%) of 
33 patients in the ketamine group and 22 (60%) of 37 in 
the saline group. On fitting a Cox model, the estimated 
hazard ratio [HR] for ketamine compared with saline was 
1·16 (95% CI 0·51–2·64, p=0·73) in favour of remission 
in the ketamine group, a non-significant difference 
(appendix). The mean number of ECT treatments to 
achieve remission was 10·0 (SD 4·7) for the ketamine 
group and 7·0 (3·6) for the saline group. Applying a linear 
regression model, adjusting for the prespecified baseline 
covariates and baseline MADRS score, the mean number 
of ECT treatments to achieve remission for patients in the 
ketamine group was –0·83 (95% CI –4·9 to 3·2, p=0·67) 
greater than on saline, a non-significant difference.
In the ketamine group, four (16%) of 25 patients 
worsened (MADRS ≥4 point increase and CGI severity ≥3) 
during follow-up compared with eight (35%) of 23 in the 
saline group (Fisher’s exact test p=0·19). One other 
patient met remission criteria by the end of follow-up in 
the ketamine group, and five more in the saline group; 
with 42·4% in the ketamine group and 48·6% in the 
saline group reaching remission by the end of study.
Seven serious adverse events occurred during the study 
(two in the ketamine group and five in the saline group) 
with no serious adverse reactions. Five serious adverse 
events involved worsening of depression (four with self-
harm) and one each of chest pain and spontaneous 
Ketamine group Saline group Treatment effect
Mean score 
(SD)
n Mean score 
(SD)
n Estimated 
difference in 
slopes (95% CI)
p value
MADRS
Baseline 31·8 (7·4) 33 35·2 (8·4) 37 ·· ··
Mid-ECT* 25·4 (9·8) 31 25·9 (12·4) 33 ·· ··
End of treatment 17·2 (11·6) 27 15·0 (10·4) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· –0·44 
(–1·91 to 1·03)
0·56
1-month follow-up 16·8 (13·6) 24 14·8 (11·4) 23 ·· ··
4-month follow-up 18·0 (13·3) 19 13·5 (13·9) 18 ·· ··
CAS
Baseline 7·79 (4·53) 33 9·16 (5·23) 37 ·· ··
Mid-ECT* 7·39 (5·29) 31 7·48 (5·37) 33 ·· ··
End of treatment 5·44 (4·04) 27 5·16 (4·34) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· –0·02 
(–0·42 to 0·38)
0·93
1-month follow-up 4·96 (4·62) 24 4·43 (·89) 23 ·· ··
4-month follow-up 4·95 (4·73) 19 3·67 (4·92) 18 ·· ··
BPRS
Baseline 37·3 (5·4) 33 40·0 (8·6) 37 ·· ··
Mid-ECT* 35·1 (6·9) 31 35·4 (8·5) 33 ·· ··
End of treatment 29·6 (6·9) 26 28·3 (6·1) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· –0·02 
(–0·73 to 0·70)
0·97
1-month follow-up 28·8 (7·8) 24 27·6 (6·4) 23 ·· ··
4-month follow-up 30·3 (8·3) 19 27·1 (8·3) 18 ·· ··
CGI-Severity
Baseline 5·03 (0·85) 33 5·30 (0·97) 37 ·· ··
Mid-ECT* 4·48 (1·12) 31 4·24 (1·35) 33 ·· ··
End of treatment 3·33 (1·33) 27 2·88 (1·24) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· –0·03 
(–0·18 to 0·13)
0·73
1-month follow-up 2·79 (1·56) 24 2·57 (1·27) 23 ·· ··
4-month follow-up 3·00 (1·60) 19 2·17 (1·34) 18 ·· ··
CGI-Improvement
Mid-ECT* 3·03 (1·02) 31 3·00 (1·09) 33 ·· ··
End of treatment 2·52 (1·31) 27 2·25 (1·11) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· 0·03 
(–0·11 to 0·17)
0·69
1-month follow-up 2·13 (1·26) 24 2·00 (1·04) 23 ·· ··
4-month follow-up 2·42 (1·35) 19 2·11 (1·41) 18 ·· ··
(Table 4 continues on next page)
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seizures between ECT treatments (both in the saline 
group; table 5). In the ketamine group, 22 adverse events 
were reported in 15 (45%) of 33 patients compared 
with ten (27%) of 37 patients in the saline group, 
who had 13 adverse events, a non-significant difference. 
Three patients given ketamine had four adverse 
reactions that did not lead to treatment discontinuation. 
One participant had transient asymptomatic increased 
liver enzymes during ECT treatment, and two patients in 
the ketamine group experienced psychological effects 
after individual ECT treatments that did not recur, one of 
whom subsequently had vivid dreams.
Discussion
This randomised trial tested the hypothesis that low-dose 
ketamine given alongside a course of ECT treatment 
would improve outcomes for depression. We found no 
evidence of benefit from adjunctive ketamine given at a 
dose of 0·5 mg/kg on cognitive and efficacy outcomes in 
patients being treated with ECT for depression. However, 
the lower than predicted recruitment means that small-
to-moderate sized benefits and moderate-to-large sized 
harms of ketamine cannot be excluded. For the primary 
outcome at mid-ECT, an effect size benefit for ketamine 
of 0·3 or greater has been excluded with 95% confidence, 
and an effect size of 0·4 or greater excluded for other key 
outcomes; this is less than the moderate effect size 
originally proposed as clinically important. Two patients 
in the ketamine group had transient psychological effects 
following isolated ECT treatments that were probably 
related to ketamine, but there was no evidence of serious 
tolerability or safety problems with ketamine given at the 
dose provided in the study.
The rationale for the trial was the protective effect of 
ketamine on adverse cognitive effects in animal studies 
of electroconvulsive shock25 and from preliminary 
human data with ECT.26–28 Since designing this study, 
further small-to-medium studies (with 15–66 patients 
per treatment group) have produced inconsistent 
findings. A randomised trial24 using ultra-brief right 
unilateral ECT with similar neuropsychological tests to 
those in our study found no effect of ketamine 
(0·5 mg/kg) as an adjunct to thiopental. Three 
randomised trials have reported potential benefits on 
some of the outcomes used in this trial. Zhong and 
colleagues29 randomly assigned participants receiving 
ECT to receive either ketamine alone (0·8 mg/kg), 
ketamine (0·5 mg/kg) adjunctive to propofol (0·5 mg/
kg), or propofol alone (0·8 mg/kg); the authors reported 
less impairment in frontal executive function only in 
participants who received ketamine alone, but no group 
differences were observed in verbal fluency, digit span, or 
the digit symbol test. Yoosefi and colleagues30 reported 
that ketamine (1–2 mg/kg) might prevent a decline in the 
MMSE after ECT compared with thiopental. The largest 
published randomised trial so far31 has reported that 
ketamine (0·3 mg/kg) as an adjunct to propofol 
Ketamine group Saline group Treatment effect
Mean score 
(SD)
n Mean score 
(SD)
n Estimated 
difference in 
slopes (95% CI)
p value
(Continued from previous page)
QIDS-SR
Baseline 17·9 (4·9) 33 20·0 (3·9) 37 ·· ··
Mid-ECT* 14·1 (5·6) 31 16·0 (5·9) 33 ·· ··
End of treatment 11·9 (6·2) 27 11·0 (5·8) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· –0·30 
(–0·88 to 0·29)
0·32
1-month follow-up 12·0 (7·5) 24 10·1 (6·2) 23 ·· ··
4-month follow-up 12·5 (7·7) 19 9·4 (7·5) 18 ·· ··
EQ-5D-3L index
Baseline 0·35 (0·27) 33 0·35 (0·28) 37 ·· ··
Mid-ECT* 0·55 (0·28) 31 0·44 (0·38) 33 ·· ··
End of treatment 0·66 (0·26) 27 0·70 (0·27) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· 0·01 
(–0·01 to 0·03)
0·43
1-month follow-up 0·67 (0·33) 24 0·71 (0·29) 23 ·· ··
4-month follow-up 0·60 (0·33) 19 0·71 (0·34) 18 ·· ··
EQ-5D-3L VAS
Baseline 31·9 (14·6) 33 24·2 (16·9) 37 ·· ··
Mid-ECT* 42·0 (18·6) 31 33·6 (22·2) 33 ·· ··
End of treatment 51·4 (22·3) 26 52·2 (21·9) 32 ·· ··
Ketamine vs saline 
from baseline up to 
end of treatment
·· ·· ·· ·· 1·16 
(–1·09 to 3·41)
0·31
1-month follow-up 53·0 (26·4) 24 54·8 (30·2) 23 ·· ··
4-month follow-up 46·2 (24·6) 19 62·4 (31·1) 18 ·· ··
Values are means (SD) and n for valid assessments at each timepoint, and estimated difference in slopes (95% CI) for 
modified intention-to-treat treatment linear random effects analysis during ECT treatment alone adjusting for age at 
randomisation, sex, baseline degree of treatment resistance, electrode placement (bilateral or unilateral), and baseline 
value. Negative values favour saline. BPRS=Brief Psychiatric Rating Scale (18-item). CAS=Clinical Anxiety Scale 
(6-item). CGI=Clinical Global Impression. EQ-5D-3L (VAS)=EuroQol 3 level version (Visual Analogue Scale). 
MADRS=Montgomery-Åsberg Depression Rating Scale. QIDS-SR=Quick Inventory of Depression Symptomatology-Self 
Report. *Mid-ECT for these outcomes were defined as 2 weeks after baseline.
Table 4: Efficacy outcomes in participants randomised to ketamine or saline
Ketamine group 
(n=33)
Saline group 
(n=37)
Infections and infestations 3 (9%) 0
Musculoskeletal and connective tissue 
disorders
2 (6%) 0
Nervous system disorders 2 (6%) 1 (3%)
Psychiatric disorders 5 (15%) 7 (19%)
Skin and subcutaneous tissue disorders 2 (6%) 0
Data are n (%). Patients experiencing more than one occurrence of an adverse 
event in a system organ class (as defined in the Medical Dictionary for Regulatory 
Activities [MedDRA]) are counted once. Values include serious adverse events and 
adverse reactions.
Table 5: Details of adverse events or reactions with a frequency of 
greater than 5%
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significantly reduced the effect of ECT on a range of 
aspects of memory using a modified Chinese version 
of the Wechsler Memory Scale. By contrast, Rybakowski 
and colleagues,32 in a non-randomised prospective study, 
found that ketamine (1–1·5 mg/kg) as an adjunct to 
thiopental at alternate ECT sessions worsened verbal 
memory and had a trend to worsen letter fluency, but did 
not affect executive function, visual memory, or digit 
span compared with thiopental alone. Similarly, results 
for reorientation after ECT are conflicting; one 
randomised trial found adjunctive ketamine (0·3 mg/kg) 
led to more rapid re-orientation compared with propofol 
alone,33 while a randomised crossover study with 
ketamine (1 mg/kg) delayed reorientation compared with 
methohexital.34 Interpretation of the literature is made 
difficult by small sample sizes and differences in 
methods used by different groups. Our results appear to 
directly contrast with those of Chen and colleagues;31 
however, differences in methods include the use of a 
1 ms pulse width stimulus, ECT given three times a 
week, a lower ketamine dose, and a Chinese population 
that had considerably greater memory impairment from 
ECT than in our study. It is uncertain how far their 
results can be extrapolated to ECT as given in the UK.
The efficacy evidence is also variable. A meta-analysis 
that collated data from five randomised trials found no 
difference in efficacy between patients treated with 
ketamine or placebo;18 by contrast, a previous meta-
analysis included four of these studies and reported a 
significant benefit for ketamine given with ECT early in 
the treatment course.17 We found a further six randomised 
trials not included in these meta-analyses. Four found no 
greater efficacy with ketamine,31,33,35,36 and two reported 
greater efficacy in the ketamine-treated group,29,37 although 
of these two studies, there is uncertainty about the 
statistical robustness in one37 and the plausibility of the 
clinical responses seen in the other.29 The study reported 
here found a small numerical advantage in the saline-
treated group with the 95% confidence interval excluding 
more than small-to-moderate advantage with ketamine 
treatment.
Some studies have suggested that ketamine could 
accelerate the clinical response to ECT,17,24,29–31,38 but we 
did not find any evidence for this and, on average, 
participants treated with ketamine achieved remission 
later than those on saline, although this observation was 
not significant. This is in sharp contrast to the rapid 
antidepressant effect within hours or days reported 
when ketamine is given alone.17 Explanations for this 
apparent discrepancy could include ECT blocking the 
effects of ketamine (possibly suggesting involvement in 
a common pathway), the requirement of a slow ketamine 
infusion rather than a bolus for the antidepressant 
effect, or requiring a subjective experience of ketamine’s 
dissociative effects.
The twice-weekly, predominantly bitemporal ECT used 
in our study with a stimulus pulse width of 0·5 ms did 
not appear to cause a substantial reduction in objective, 
or self-reported, cognitive function, and the decrease in 
AMI-SF values over time is similar to that seen in healthy 
volunteers.39 Bitemporal ECT is the standard electrode 
placement in the UK5 by use of a 0·5 ms pulse width. It 
has been suggested that a 0·5 ms pulse width causes less 
cognitive impairment than the 1·0–1·5 ms pulse widths 
predominantly reported in the literature,40 which might 
explain the modest cognitive effects we found in this 
Article, but this finding needs to be studied systematically. 
Remission rates in our study were relatively low (37%) 
compared with about half of patients remitting in 
Scotland during 2014.5 A possible explanation is that 
remission rates are lower in patients without psychosis5 
and with treatment resistance4 as was predominantly 
found in our patients.
Few studies have followed up patients after the end of 
ECT; one study found an efficacy advantage to the 
patients treated with ketamine 1 week after ECT but not 
after 1 month.24 We found no difference in cognitive or 
efficacy outcomes 4 months after ECT, although the 
dropout rate restricts interpretation, since those patients 
that discontinued treatment might be affected by clinical 
factors such as relapse or further ECT.
We did not find any major safety or tolerability 
problems attributable to ketamine, although two (6%) 
of 33 patients treated with ketamine had transient 
psychological reactions. Some studies using ketamine 
alone, or at higher doses than used in this study, have 
found it to be associated with slower reorientation and 
more adverse events than control conditions.34,35,41 These 
effects appear to be attenuated when ketamine is 
combined with propofol,41 indicating that the dose 
and context of ketamine administration is important 
when assessing its safety and tolerability with ECT.
Our study has a number of limitations. The most 
important is that the sample size was smaller than 
planned, which resulted in a low power so that we 
cannot exclude either a small to moderate sized benefit 
or moderate harm from treatment with adjunctive 
ketamine. Although we did not have differential dropout 
between treatment groups, over 40% of the patient 
population had dropped out by the 1-month follow-up 
and almost half by 4-month follow-up. We therefore 
have limited ability to say what happened to patients 
after the end of treatment timepoint. The clinical 
realities of treatment made strictly timed assessments 
difficult, but there were no systematic differences seen 
in assessment timing or delay between the treatment 
groups, and sensitivity analyses with stricter timings 
did not alter the results. The included patients were not 
fully representative of the total population of patients 
who receive ECT; in particular, they were younger and, 
based on reasons for exclusion, likely to be less 
cognitively compromised and less severely ill than non-
eligible patients so that generalisation to these more 
severely affected patients cannot be assumed; however, 
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trials in these patients would present considerable 
ethical difficulties. Finally, our results are based on one 
dose and method of administering ketamine with ECT, 
and it is possible that results could be different with 
other doses of ketamine or in the context of different 
ECT regimens or patient populations.
The place of ketamine in combination with ECT has not 
been finally defined, but our study suggests that there is 
no beneficial effect when it is given at a standard dose of 
0·5 mg during ECT as it is routinely given in the UK. 
Future research using small to moderate sample sizes is 
likely to be unhelpful in further resolving the question, 
and only a sufficiently large future study would be able to 
address this uncertainty. There are considerable practical 
difficulties in doing multicentre ECT research and the 
uncertainty about the optimum dose and method for 
administering ketamine with ECT is an important 
challenge for the design of a definitive study.
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